The first‐generation phosphodiesterase 5 inhibitors and their pharmacokinetic issue

Background Erectile dysfunction (ED) is a relatively frequent disease that negatively impacts the overall quality of life, well‐being, and relationships. Although the use of phosphodiesterase 5 inhibitors (PDE5is) has revolutionized the treatment of ED, a high percentage of ED patients discontinue P...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Andrology (Oxford) 2019-11, Vol.7 (6), p.804-817
Hauptverfasser:	Zucchi, A., Costantini, E., Scroppo, F. I., Silvani, M., Kopa, Z., Illiano, E., Petrillo, M. G., Cari, L., Nocentini, G.
Format:	Artikel
Sprache:	eng
Schlagworte:	Erectile dysfunction excipients Men ODF formulation OTF formulation Patient satisfaction PDE5 inhibitors Pharmaceuticals pharmacokinetic Pharmacokinetics Review Sexual disorders Well being
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!